Peter Gottlieb
Concepts (550)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Diabetes Mellitus, Type 1 | 133 | 2023 | 3252 | 6.740 |
Why?
| Insulin | 49 | 2023 | 2080 | 2.660 |
Why?
| Islets of Langerhans | 22 | 2023 | 726 | 1.800 |
Why?
| Insulin-Secreting Cells | 18 | 2021 | 317 | 1.740 |
Why?
| Hypoglycemic Agents | 20 | 2023 | 1013 | 1.590 |
Why?
| C-Peptide | 26 | 2023 | 138 | 1.400 |
Why?
| Autoantibodies | 33 | 2022 | 1346 | 1.310 |
Why?
| B-Lymphocytes | 9 | 2023 | 766 | 1.100 |
Why?
| Antilymphocyte Serum | 8 | 2021 | 60 | 1.040 |
Why?
| Autoantigens | 15 | 2021 | 396 | 1.010 |
Why?
| Monitoring, Ambulatory | 4 | 2010 | 81 | 0.990 |
Why?
| Autoimmunity | 19 | 2023 | 813 | 0.960 |
Why?
| Antibodies, Monoclonal, Humanized | 12 | 2023 | 663 | 0.940 |
Why?
| T-Lymphocytes | 23 | 2023 | 1737 | 0.940 |
Why?
| CD4-Positive T-Lymphocytes | 13 | 2023 | 959 | 0.900 |
Why?
| Blood Glucose | 15 | 2021 | 1828 | 0.890 |
Why?
| Immunosuppressive Agents | 9 | 2023 | 646 | 0.870 |
Why?
| Clinical Trials as Topic | 11 | 2020 | 932 | 0.790 |
Why?
| Proinsulin | 6 | 2016 | 48 | 0.780 |
Why?
| Blood Glucose Self-Monitoring | 4 | 2010 | 505 | 0.760 |
Why?
| Immunologic Factors | 7 | 2019 | 220 | 0.670 |
Why?
| CD4 Antigens | 2 | 2013 | 123 | 0.670 |
Why?
| Adult | 84 | 2023 | 30553 | 0.660 |
Why?
| Humans | 149 | 2023 | 114699 | 0.660 |
Why?
| Diabetes Mellitus, Type 2 | 6 | 2020 | 2096 | 0.660 |
Why?
| Addison Disease | 7 | 2012 | 40 | 0.640 |
Why?
| Adolescent | 67 | 2022 | 17853 | 0.640 |
Why?
| Preventive Medicine | 2 | 2018 | 40 | 0.630 |
Why?
| Prediabetic State | 7 | 2018 | 219 | 0.630 |
Why?
| Polyendocrinopathies, Autoimmune | 3 | 2010 | 18 | 0.630 |
Why?
| CD8-Positive T-Lymphocytes | 10 | 2019 | 687 | 0.610 |
Why?
| Young Adult | 44 | 2022 | 10471 | 0.570 |
Why?
| Insulin Antibodies | 6 | 2022 | 102 | 0.570 |
Why?
| Child | 60 | 2023 | 18420 | 0.560 |
Why?
| Granulocyte Colony-Stimulating Factor | 6 | 2021 | 71 | 0.550 |
Why?
| Peptide Fragments | 12 | 2016 | 666 | 0.540 |
Why?
| HLA-DQ Antigens | 10 | 2019 | 174 | 0.530 |
Why?
| Mycophenolic Acid | 3 | 2012 | 77 | 0.520 |
Why?
| Autoimmune Diseases | 10 | 2017 | 382 | 0.510 |
Why?
| Immunoglobulin G | 6 | 2018 | 770 | 0.480 |
Why?
| Monocytes | 4 | 2016 | 504 | 0.480 |
Why?
| Steroid 21-Hydroxylase | 5 | 2012 | 30 | 0.480 |
Why?
| Peptides | 4 | 2021 | 848 | 0.470 |
Why?
| Biomarkers | 12 | 2021 | 3408 | 0.470 |
Why?
| Glutamate Decarboxylase | 9 | 2022 | 160 | 0.470 |
Why?
| Mice, Inbred NOD | 16 | 2023 | 555 | 0.460 |
Why?
| Cytokines | 9 | 2018 | 1841 | 0.460 |
Why?
| Female | 83 | 2022 | 59520 | 0.450 |
Why?
| Male | 76 | 2022 | 55606 | 0.440 |
Why?
| Cystic Fibrosis | 3 | 2012 | 955 | 0.440 |
Why?
| Vaccines, DNA | 1 | 2013 | 29 | 0.440 |
Why?
| Chromogranin A | 1 | 2013 | 39 | 0.430 |
Why?
| Interferon-gamma | 6 | 2021 | 719 | 0.420 |
Why?
| Immunologic Memory | 7 | 2019 | 313 | 0.420 |
Why?
| Myeloid Cells | 1 | 2014 | 126 | 0.410 |
Why?
| Immunomodulation | 1 | 2013 | 84 | 0.410 |
Why?
| T-Lymphocyte Subsets | 8 | 2018 | 383 | 0.410 |
Why?
| alpha 1-Antitrypsin | 1 | 2014 | 103 | 0.410 |
Why?
| Disease Progression | 16 | 2021 | 2380 | 0.400 |
Why?
| Immunotherapy | 4 | 2013 | 474 | 0.400 |
Why?
| Hypoglycemia | 6 | 2009 | 387 | 0.390 |
Why?
| Dendritic Cells | 2 | 2014 | 435 | 0.380 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2014 | 299 | 0.370 |
Why?
| Diabetes Mellitus | 2 | 2023 | 900 | 0.360 |
Why?
| Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 4 | 2021 | 58 | 0.350 |
Why?
| Immunoconjugates | 4 | 2014 | 87 | 0.340 |
Why?
| CD3 Complex | 5 | 2019 | 92 | 0.330 |
Why?
| HLA-DR3 Antigen | 5 | 2022 | 79 | 0.330 |
Why?
| HLA-DR Antigens | 7 | 2018 | 219 | 0.310 |
Why?
| Antibodies, Monoclonal | 5 | 2010 | 1262 | 0.310 |
Why?
| Clonal Anergy | 3 | 2018 | 53 | 0.300 |
Why?
| Histocompatibility Antigens Class I | 5 | 2011 | 172 | 0.290 |
Why?
| Cation Transport Proteins | 3 | 2017 | 123 | 0.290 |
Why?
| Toll-Like Receptors | 3 | 2014 | 167 | 0.280 |
Why?
| Double-Blind Method | 12 | 2021 | 1660 | 0.270 |
Why?
| Age of Onset | 6 | 2020 | 446 | 0.270 |
Why?
| Area Under Curve | 8 | 2021 | 274 | 0.270 |
Why?
| Time Factors | 10 | 2020 | 6116 | 0.270 |
Why?
| Zinc Transporter 8 | 4 | 2021 | 86 | 0.260 |
Why?
| Receptors, Interleukin-2 | 2 | 2006 | 64 | 0.260 |
Why?
| Middle Aged | 35 | 2021 | 26738 | 0.250 |
Why?
| Animals | 29 | 2023 | 31708 | 0.250 |
Why?
| Software | 2 | 2008 | 530 | 0.250 |
Why?
| Antigen Presentation | 3 | 2018 | 188 | 0.240 |
Why?
| Insulin, Regular, Human | 2 | 2023 | 33 | 0.240 |
Why?
| Insulin, Isophane | 1 | 2004 | 18 | 0.240 |
Why?
| Precision Medicine | 3 | 2023 | 337 | 0.230 |
Why?
| T-Lymphocytes, Regulatory | 6 | 2023 | 339 | 0.230 |
Why?
| Pregnancy in Diabetics | 2 | 2003 | 82 | 0.230 |
Why?
| Antibodies, Monoclonal, Murine-Derived | 3 | 2013 | 82 | 0.220 |
Why?
| Protein Precursors | 2 | 2016 | 119 | 0.220 |
Why?
| Mice | 23 | 2023 | 14871 | 0.220 |
Why?
| Immunotherapy, Active | 2 | 2014 | 8 | 0.210 |
Why?
| Polyethylene Glycols | 3 | 2018 | 561 | 0.210 |
Why?
| Plasmids | 3 | 2013 | 343 | 0.210 |
Why?
| Islets of Langerhans Transplantation | 2 | 2015 | 53 | 0.200 |
Why?
| Histocompatibility Testing | 4 | 2013 | 116 | 0.200 |
Why?
| Epitopes, T-Lymphocyte | 4 | 2011 | 170 | 0.200 |
Why?
| Immune Tolerance | 2 | 2017 | 323 | 0.200 |
Why?
| Interleukin-1beta | 3 | 2014 | 370 | 0.200 |
Why?
| Lymphocyte Depletion | 2 | 2013 | 116 | 0.200 |
Why?
| Receptors, Antigen, T-Cell | 5 | 2022 | 615 | 0.200 |
Why?
| Treatment Outcome | 11 | 2020 | 9088 | 0.190 |
Why?
| Methyldopa | 2 | 2019 | 7 | 0.190 |
Why?
| Recombinant Fusion Proteins | 2 | 2015 | 616 | 0.190 |
Why?
| Imatinib Mesylate | 1 | 2021 | 63 | 0.190 |
Why?
| Genetic Predisposition to Disease | 8 | 2018 | 2086 | 0.190 |
Why?
| Necrobiosis Lipoidica | 1 | 2001 | 2 | 0.180 |
Why?
| Haplotypes | 5 | 2022 | 448 | 0.180 |
Why?
| Dose-Response Relationship, Drug | 5 | 2019 | 1842 | 0.180 |
Why?
| Asymptomatic Diseases | 1 | 2021 | 75 | 0.180 |
Why?
| History, 21st Century | 2 | 2018 | 159 | 0.180 |
Why?
| Histocompatibility Antigens Class II | 3 | 2011 | 352 | 0.180 |
Why?
| Platelet-Derived Growth Factor | 1 | 2001 | 82 | 0.180 |
Why?
| Glucagon-Like Peptides | 1 | 2020 | 22 | 0.180 |
Why?
| Child, Preschool | 17 | 2022 | 9118 | 0.180 |
Why?
| Gastrointestinal Microbiome | 2 | 2018 | 501 | 0.180 |
Why?
| History, 20th Century | 2 | 2018 | 264 | 0.180 |
Why?
| Biomarkers, Pharmacological | 1 | 2020 | 26 | 0.170 |
Why?
| Interleukin-7 Receptor alpha Subunit | 1 | 2019 | 11 | 0.170 |
Why?
| Cytomegalovirus | 2 | 2018 | 144 | 0.170 |
Why?
| Biological Variation, Population | 1 | 2019 | 19 | 0.170 |
Why?
| Hepatitis Delta Virus | 3 | 1994 | 6 | 0.170 |
Why?
| Luminescence | 2 | 2016 | 33 | 0.170 |
Why?
| Graves Disease | 2 | 2017 | 32 | 0.170 |
Why?
| Th2 Cells | 2 | 2014 | 154 | 0.170 |
Why?
| Forkhead Transcription Factors | 3 | 2016 | 170 | 0.160 |
Why?
| Biomedical Research | 2 | 2018 | 585 | 0.160 |
Why?
| Cytoprotection | 1 | 2018 | 51 | 0.150 |
Why?
| Immunity, Cellular | 2 | 2018 | 248 | 0.150 |
Why?
| Diabetes Mellitus, Experimental | 2 | 1990 | 160 | 0.150 |
Why?
| Inflammation | 4 | 2018 | 2480 | 0.150 |
Why?
| Thyroiditis, Autoimmune | 1 | 2017 | 13 | 0.150 |
Why?
| HLA-A2 Antigen | 1 | 2017 | 36 | 0.150 |
Why?
| Abatacept | 5 | 2023 | 40 | 0.150 |
Why?
| Twins, Dizygotic | 1 | 2018 | 182 | 0.150 |
Why?
| HLA-DR4 Antigen | 4 | 2022 | 76 | 0.140 |
Why?
| Lymphocyte Activation | 6 | 2017 | 1037 | 0.140 |
Why?
| Thyroid Gland | 1 | 2017 | 82 | 0.140 |
Why?
| Twins, Monozygotic | 1 | 2018 | 210 | 0.140 |
Why?
| Treatment Failure | 1 | 2018 | 331 | 0.140 |
Why?
| Antibody-Producing Cells | 1 | 2017 | 29 | 0.140 |
Why?
| Regeneration | 1 | 1998 | 160 | 0.140 |
Why?
| Th1 Cells | 2 | 2009 | 123 | 0.140 |
Why?
| Cell Separation | 2 | 2017 | 291 | 0.140 |
Why?
| Magnetic Fields | 1 | 2017 | 22 | 0.140 |
Why?
| Dysbiosis | 1 | 2018 | 146 | 0.140 |
Why?
| Follow-Up Studies | 8 | 2021 | 4411 | 0.140 |
Why?
| Influenza, Human | 1 | 2022 | 546 | 0.140 |
Why?
| Antibody Formation | 1 | 2018 | 266 | 0.140 |
Why?
| Glucose Tolerance Test | 4 | 2021 | 343 | 0.140 |
Why?
| Cytomegalovirus Infections | 1 | 2018 | 180 | 0.130 |
Why?
| Trans-Activators | 1 | 1998 | 367 | 0.130 |
Why?
| Administration, Oral | 1 | 2018 | 728 | 0.130 |
Why?
| Nanoparticles | 2 | 2017 | 313 | 0.130 |
Why?
| RNA, Catalytic | 2 | 1994 | 182 | 0.130 |
Why?
| Protein Kinase Inhibitors | 1 | 2021 | 785 | 0.130 |
Why?
| Host-Pathogen Interactions | 1 | 2018 | 295 | 0.130 |
Why?
| Tuftsin | 3 | 1983 | 4 | 0.120 |
Why?
| Homeodomain Proteins | 1 | 1998 | 463 | 0.120 |
Why?
| Drug Therapy, Combination | 3 | 2018 | 951 | 0.120 |
Why?
| Dermatologic Agents | 1 | 2015 | 57 | 0.120 |
Why?
| Epitopes | 4 | 2017 | 435 | 0.120 |
Why?
| Phenotype | 2 | 2019 | 2797 | 0.120 |
Why?
| Family | 2 | 2017 | 589 | 0.120 |
Why?
| Risk Factors | 12 | 2018 | 8632 | 0.120 |
Why?
| Receptors, Antigen, T-Cell, alpha-beta | 3 | 2022 | 309 | 0.120 |
Why?
| Graft Rejection | 2 | 2015 | 513 | 0.110 |
Why?
| Law Enforcement | 1 | 2014 | 37 | 0.110 |
Why?
| Crime | 1 | 2014 | 59 | 0.110 |
Why?
| Criminals | 1 | 2014 | 29 | 0.110 |
Why?
| Withholding Treatment | 1 | 2013 | 68 | 0.110 |
Why?
| Pancreatectomy | 1 | 2015 | 171 | 0.110 |
Why?
| Primary Cell Culture | 1 | 2013 | 149 | 0.110 |
Why?
| Transglutaminases | 1 | 2013 | 142 | 0.110 |
Why?
| Reproducibility of Results | 3 | 2009 | 2765 | 0.110 |
Why?
| Cytotoxicity, Immunologic | 2 | 2013 | 195 | 0.100 |
Why?
| Adjuvants, Immunologic | 1 | 2014 | 206 | 0.100 |
Why?
| Gene Expression | 2 | 2013 | 1421 | 0.100 |
Why?
| Communicable Diseases | 1 | 2014 | 129 | 0.100 |
Why?
| Sensitivity and Specificity | 2 | 2009 | 1693 | 0.100 |
Why?
| Nucleic Acid Conformation | 3 | 1994 | 669 | 0.100 |
Why?
| Adaptive Immunity | 1 | 2013 | 155 | 0.100 |
Why?
| Cross-Sectional Studies | 6 | 2023 | 4410 | 0.100 |
Why?
| DNA, Viral | 1 | 1994 | 350 | 0.100 |
Why?
| Receptors, Immunologic | 2 | 1983 | 201 | 0.100 |
Why?
| Flow Cytometry | 4 | 2019 | 1083 | 0.100 |
Why?
| Proportional Hazards Models | 3 | 2021 | 1075 | 0.100 |
Why?
| Alleles | 5 | 2011 | 789 | 0.100 |
Why?
| Diabetic Angiopathies | 2 | 2010 | 244 | 0.100 |
Why?
| Epstein-Barr Virus Infections | 1 | 2012 | 72 | 0.100 |
Why?
| Polymorphism, Genetic | 3 | 2010 | 610 | 0.090 |
Why?
| Down-Regulation | 1 | 2014 | 594 | 0.090 |
Why?
| Thyroiditis | 1 | 1991 | 3 | 0.090 |
Why?
| Cells, Cultured | 7 | 2017 | 3886 | 0.090 |
Why?
| Pilot Projects | 3 | 2021 | 1373 | 0.090 |
Why?
| Recombinant Proteins | 3 | 2018 | 1230 | 0.090 |
Why?
| Herpesviridae Infections | 1 | 2012 | 138 | 0.090 |
Why?
| Lymphocyte Count | 3 | 2019 | 133 | 0.090 |
Why?
| Interleukin-6 | 2 | 2012 | 676 | 0.090 |
Why?
| HLA-B Antigens | 1 | 2011 | 56 | 0.090 |
Why?
| Organophosphorus Compounds | 1 | 2011 | 72 | 0.090 |
Why?
| Glycine | 1 | 2011 | 152 | 0.090 |
Why?
| Cryopreservation | 1 | 2011 | 92 | 0.090 |
Why?
| Drug Delivery Systems | 1 | 2013 | 296 | 0.090 |
Why?
| Endocrine Cells | 1 | 2010 | 6 | 0.090 |
Why?
| Transplantation Immunology | 1 | 1990 | 30 | 0.090 |
Why?
| HLA Antigens | 4 | 2022 | 225 | 0.090 |
Why?
| Insulin, Long-Acting | 3 | 2004 | 53 | 0.090 |
Why?
| Mental Health Services | 1 | 2014 | 317 | 0.090 |
Why?
| Insulin Glargine | 3 | 2004 | 73 | 0.080 |
Why?
| Inflammation Mediators | 2 | 2010 | 477 | 0.080 |
Why?
| Genotype | 5 | 2015 | 1760 | 0.080 |
Why?
| Prognosis | 4 | 2021 | 3329 | 0.080 |
Why?
| Randomized Controlled Trials as Topic | 4 | 2018 | 1214 | 0.080 |
Why?
| Molecular Sequence Data | 8 | 2015 | 2785 | 0.080 |
Why?
| Enzyme-Linked Immunosorbent Assay | 4 | 2014 | 797 | 0.080 |
Why?
| Muromonab-CD3 | 1 | 2009 | 20 | 0.080 |
Why?
| Insulin Infusion Systems | 2 | 2004 | 299 | 0.080 |
Why?
| T-Lymphocytes, Cytotoxic | 2 | 2009 | 154 | 0.080 |
Why?
| Bacteria | 1 | 2015 | 725 | 0.080 |
Why?
| Adrenocorticotropic Hormone | 2 | 2012 | 128 | 0.080 |
Why?
| Antigens | 3 | 2023 | 318 | 0.080 |
Why?
| Amino Acid Sequence | 7 | 2015 | 1982 | 0.080 |
Why?
| Interleukin-17 | 1 | 2009 | 104 | 0.080 |
Why?
| Receptors, Chemokine | 2 | 2007 | 44 | 0.080 |
Why?
| Vitamin D Deficiency | 1 | 2010 | 158 | 0.080 |
Why?
| Immunodominant Epitopes | 2 | 2006 | 25 | 0.080 |
Why?
| Calcinosis | 1 | 2010 | 242 | 0.080 |
Why?
| Remission Induction | 2 | 2018 | 233 | 0.070 |
Why?
| Hydrocortisone | 2 | 2012 | 267 | 0.070 |
Why?
| Disease Models, Animal | 2 | 2009 | 3535 | 0.070 |
Why?
| Consensus | 2 | 2023 | 537 | 0.070 |
Why?
| Platelet Membrane Glycoprotein IIb | 1 | 2007 | 4 | 0.070 |
Why?
| Case-Control Studies | 5 | 2016 | 3003 | 0.070 |
Why?
| Homicide | 1 | 1988 | 53 | 0.070 |
Why?
| Regression Analysis | 1 | 2010 | 945 | 0.070 |
Why?
| Enzyme-Linked Immunospot Assay | 3 | 2011 | 34 | 0.070 |
Why?
| Equipment Design | 1 | 2009 | 508 | 0.070 |
Why?
| Safety | 1 | 2009 | 298 | 0.070 |
Why?
| Killer Cells, Natural | 2 | 2016 | 380 | 0.070 |
Why?
| Rituximab | 3 | 2013 | 150 | 0.070 |
Why?
| Radioimmunoassay | 2 | 2017 | 162 | 0.070 |
Why?
| Atherosclerosis | 1 | 2010 | 341 | 0.070 |
Why?
| CD40 Antigens | 1 | 2007 | 82 | 0.070 |
Why?
| Receptors, Interleukin-7 | 1 | 2006 | 25 | 0.070 |
Why?
| CD4 Lymphocyte Count | 3 | 2015 | 257 | 0.070 |
Why?
| Mutation | 4 | 2015 | 3346 | 0.070 |
Why?
| Mental Disorders | 1 | 2014 | 893 | 0.070 |
Why?
| Hybridomas | 2 | 2004 | 230 | 0.060 |
Why?
| Diabetic Retinopathy | 2 | 2005 | 149 | 0.060 |
Why?
| Proteins | 2 | 2018 | 908 | 0.060 |
Why?
| Signal Transduction | 3 | 2019 | 4515 | 0.060 |
Why?
| Isoenzymes | 2 | 2004 | 283 | 0.060 |
Why?
| Disease Susceptibility | 2 | 2019 | 316 | 0.060 |
Why?
| Protein Tyrosine Phosphatases | 2 | 2004 | 147 | 0.060 |
Why?
| Urban Population | 1 | 1988 | 397 | 0.060 |
Why?
| Acetamides | 1 | 2005 | 25 | 0.060 |
Why?
| Chemokines, CXC | 1 | 2005 | 60 | 0.060 |
Why?
| Risk | 3 | 2019 | 812 | 0.060 |
Why?
| Coronary Artery Disease | 1 | 2010 | 607 | 0.060 |
Why?
| Feces | 2 | 2018 | 373 | 0.060 |
Why?
| Immunophenotyping | 2 | 2018 | 274 | 0.060 |
Why?
| Exanthema | 2 | 2019 | 74 | 0.060 |
Why?
| Blood Coagulation Factors | 1 | 1984 | 44 | 0.060 |
Why?
| Age Factors | 3 | 2017 | 2894 | 0.060 |
Why?
| Niacinamide | 1 | 2004 | 63 | 0.060 |
Why?
| Immunoglobulin Fragments | 1 | 1983 | 15 | 0.060 |
Why?
| Tissue Donors | 1 | 2006 | 316 | 0.050 |
Why?
| Leukocytes, Mononuclear | 2 | 2019 | 493 | 0.050 |
Why?
| Immunoassay | 1 | 2003 | 95 | 0.050 |
Why?
| Mice, Knockout | 1 | 2009 | 2570 | 0.050 |
Why?
| Placebos | 2 | 2013 | 197 | 0.050 |
Why?
| Intercellular Signaling Peptides and Proteins | 1 | 2005 | 351 | 0.050 |
Why?
| Cell Survival | 2 | 2019 | 1021 | 0.050 |
Why?
| Interleukin-4 | 2 | 2002 | 206 | 0.050 |
Why?
| Antigens, CD1 | 1 | 2002 | 57 | 0.050 |
Why?
| Cell Differentiation | 1 | 2009 | 1701 | 0.050 |
Why?
| Siblings | 2 | 2018 | 221 | 0.050 |
Why?
| Antibody Affinity | 2 | 2016 | 52 | 0.050 |
Why?
| Gene Frequency | 2 | 2016 | 477 | 0.050 |
Why?
| Receptors, CXCR3 | 2 | 2016 | 15 | 0.050 |
Why?
| Pyrimidines | 1 | 2005 | 376 | 0.050 |
Why?
| Cell Proliferation | 2 | 2009 | 2187 | 0.050 |
Why?
| Canada | 2 | 2014 | 322 | 0.050 |
Why?
| Preconception Care | 1 | 2002 | 31 | 0.050 |
Why?
| Labor, Obstetric | 1 | 2002 | 52 | 0.050 |
Why?
| Diseases in Twins | 2 | 2018 | 174 | 0.050 |
Why?
| Algorithms | 1 | 2008 | 1470 | 0.050 |
Why?
| Reference Values | 3 | 2009 | 743 | 0.050 |
Why?
| Denmark | 2 | 2014 | 39 | 0.050 |
Why?
| Pancreas | 2 | 2018 | 276 | 0.050 |
Why?
| Bacterial Proteins | 2 | 2018 | 736 | 0.050 |
Why?
| Proto-Oncogene Proteins c-sis | 1 | 2001 | 35 | 0.050 |
Why?
| Pregnancy Outcome | 1 | 2003 | 337 | 0.050 |
Why?
| Infant | 4 | 2022 | 7964 | 0.050 |
Why?
| Vitamin D | 1 | 2004 | 341 | 0.040 |
Why?
| Administration, Topical | 1 | 2001 | 138 | 0.040 |
Why?
| Membrane Proteins | 2 | 2004 | 1019 | 0.040 |
Why?
| Venoms | 1 | 2020 | 30 | 0.040 |
Why?
| Kinetics | 4 | 1994 | 1551 | 0.040 |
Why?
| Rats, Inbred BB | 2 | 1991 | 5 | 0.040 |
Why?
| Hemorrhage | 1 | 1984 | 620 | 0.040 |
Why?
| Diagnostic Techniques, Endocrine | 1 | 2020 | 14 | 0.040 |
Why?
| Lymphocytes | 1 | 2002 | 330 | 0.040 |
Why?
| HLA-DR2 Antigen | 1 | 1999 | 8 | 0.040 |
Why?
| Dose-Response Relationship, Immunologic | 1 | 2019 | 75 | 0.040 |
Why?
| Antibodies, Heterophile | 1 | 1999 | 13 | 0.040 |
Why?
| ROC Curve | 1 | 2021 | 442 | 0.040 |
Why?
| Prospective Studies | 4 | 2016 | 6220 | 0.040 |
Why?
| Databases, Factual | 1 | 2004 | 1125 | 0.040 |
Why?
| Interleukin-7 | 1 | 2019 | 45 | 0.040 |
Why?
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 3 | 2007 | 44 | 0.040 |
Why?
| Genes, MHC Class II | 1 | 1999 | 69 | 0.040 |
Why?
| Mice, Inbred BALB C | 4 | 2011 | 1144 | 0.040 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2022 | 439 | 0.040 |
Why?
| HLA-A Antigens | 2 | 2011 | 49 | 0.040 |
Why?
| Evidence-Based Medicine | 1 | 2023 | 668 | 0.040 |
Why?
| CD4-CD8 Ratio | 1 | 2019 | 19 | 0.040 |
Why?
| Macrophages | 2 | 1983 | 1263 | 0.040 |
Why?
| Postpartum Period | 1 | 2002 | 278 | 0.040 |
Why?
| Lymphopenia | 1 | 2019 | 49 | 0.040 |
Why?
| Leg | 1 | 2001 | 225 | 0.040 |
Why?
| Methylation | 1 | 2019 | 208 | 0.040 |
Why?
| RNA, Viral | 2 | 1992 | 565 | 0.040 |
Why?
| Mucosal-Associated Invariant T Cells | 1 | 2018 | 16 | 0.040 |
Why?
| Wound Healing | 1 | 2001 | 258 | 0.040 |
Why?
| Meals | 1 | 2020 | 104 | 0.040 |
Why?
| Seroconversion | 1 | 2018 | 45 | 0.040 |
Why?
| Insulin Lispro | 3 | 2004 | 35 | 0.040 |
Why?
| Risk Assessment | 2 | 2018 | 2968 | 0.040 |
Why?
| Therapies, Investigational | 1 | 2018 | 14 | 0.040 |
Why?
| Glucose | 1 | 2023 | 897 | 0.040 |
Why?
| United States | 4 | 2015 | 12186 | 0.040 |
Why?
| Seroepidemiologic Studies | 1 | 2018 | 138 | 0.040 |
Why?
| Protein Tyrosine Phosphatase, Non-Receptor Type 2 | 1 | 2018 | 11 | 0.040 |
Why?
| B7-2 Antigen | 1 | 2017 | 25 | 0.040 |
Why?
| Aged | 6 | 2014 | 19074 | 0.040 |
Why?
| Ikaros Transcription Factor | 1 | 2018 | 17 | 0.040 |
Why?
| Base Sequence | 4 | 1994 | 2114 | 0.040 |
Why?
| Single-Cell Analysis | 1 | 2019 | 188 | 0.040 |
Why?
| Cell Death | 1 | 2019 | 323 | 0.040 |
Why?
| Rats | 3 | 1991 | 4958 | 0.040 |
Why?
| Mice, Transgenic | 2 | 2018 | 1950 | 0.040 |
Why?
| Antigens, CD | 2 | 2014 | 442 | 0.040 |
Why?
| Patient Care Planning | 1 | 2018 | 139 | 0.040 |
Why?
| Drug Discovery | 1 | 2018 | 123 | 0.040 |
Why?
| Structure-Activity Relationship | 2 | 2011 | 502 | 0.030 |
Why?
| Clone Cells | 3 | 2004 | 247 | 0.030 |
Why?
| Twins | 1 | 2018 | 240 | 0.030 |
Why?
| Genetic Markers | 1 | 1998 | 320 | 0.030 |
Why?
| Controlled Clinical Trials as Topic | 1 | 2016 | 27 | 0.030 |
Why?
| CD56 Antigen | 1 | 2016 | 34 | 0.030 |
Why?
| Luminescent Measurements | 1 | 2017 | 74 | 0.030 |
Why?
| Predictive Value of Tests | 2 | 2012 | 1796 | 0.030 |
Why?
| Leukocyte Common Antigens | 2 | 2007 | 75 | 0.030 |
Why?
| Environment | 1 | 2018 | 332 | 0.030 |
Why?
| Receptors, IgG | 1 | 2016 | 67 | 0.030 |
Why?
| Cohort Studies | 3 | 2015 | 4895 | 0.030 |
Why?
| Cell Count | 1 | 2017 | 303 | 0.030 |
Why?
| Somalia | 1 | 2016 | 8 | 0.030 |
Why?
| Forecasting | 1 | 1998 | 330 | 0.030 |
Why?
| Antibody Specificity | 2 | 2007 | 176 | 0.030 |
Why?
| Orphan Drug Production | 1 | 2015 | 6 | 0.030 |
Why?
| Cities | 1 | 2016 | 80 | 0.030 |
Why?
| Organ Specificity | 2 | 2007 | 268 | 0.030 |
Why?
| Minnesota | 1 | 2016 | 134 | 0.030 |
Why?
| Intestines | 1 | 2018 | 326 | 0.030 |
Why?
| Immunity, Humoral | 1 | 2016 | 112 | 0.030 |
Why?
| Ethics, Medical | 1 | 2015 | 70 | 0.030 |
Why?
| HLA-DRB1 Chains | 2 | 2009 | 98 | 0.030 |
Why?
| Immunity, Innate | 2 | 2009 | 720 | 0.030 |
Why?
| Immunity, Active | 1 | 2014 | 9 | 0.030 |
Why?
| Transplantation, Autologous | 1 | 2015 | 176 | 0.030 |
Why?
| Early Diagnosis | 1 | 2015 | 217 | 0.030 |
Why?
| Proline | 1 | 1994 | 72 | 0.030 |
Why?
| Sequence Homology, Amino Acid | 1 | 2015 | 353 | 0.030 |
Why?
| Immunoglobulins | 1 | 2014 | 143 | 0.030 |
Why?
| Opportunistic Infections | 1 | 2014 | 43 | 0.030 |
Why?
| Single-Blind Method | 1 | 2014 | 258 | 0.030 |
Why?
| Body Mass Index | 1 | 2021 | 1959 | 0.030 |
Why?
| Drug Combinations | 1 | 2014 | 287 | 0.030 |
Why?
| Protein Structure, Secondary | 1 | 1994 | 325 | 0.030 |
Why?
| Cloning, Molecular | 1 | 2014 | 522 | 0.030 |
Why?
| Pregnancy | 2 | 2003 | 5520 | 0.030 |
Why?
| Sequence Deletion | 1 | 1994 | 167 | 0.030 |
Why?
| Cost of Illness | 1 | 2015 | 254 | 0.030 |
Why?
| Europe | 1 | 2014 | 334 | 0.030 |
Why?
| Polymorphism, Single Nucleotide | 2 | 2011 | 1880 | 0.030 |
Why?
| Mutagenesis | 1 | 1994 | 168 | 0.030 |
Why?
| Transcription, Genetic | 3 | 1994 | 1313 | 0.030 |
Why?
| Cytotoxicity Tests, Immunologic | 1 | 2013 | 43 | 0.030 |
Why?
| Escherichia coli Proteins | 1 | 1994 | 162 | 0.030 |
Why?
| Interleukin-10 | 1 | 2015 | 299 | 0.030 |
Why?
| RNA, Ribosomal, 16S | 1 | 2015 | 485 | 0.030 |
Why?
| Formamides | 1 | 1992 | 6 | 0.030 |
Why?
| Herpesviridae | 1 | 2012 | 21 | 0.030 |
Why?
| Proteomics | 1 | 2018 | 836 | 0.030 |
Why?
| Graft Survival | 1 | 2015 | 446 | 0.030 |
Why?
| Immunocompromised Host | 1 | 2014 | 195 | 0.030 |
Why?
| Postprandial Period | 1 | 2013 | 87 | 0.030 |
Why?
| Lymph Nodes | 2 | 2006 | 419 | 0.030 |
Why?
| Interleukins | 1 | 2014 | 236 | 0.030 |
Why?
| Gene Expression Regulation | 2 | 2014 | 2320 | 0.030 |
Why?
| Renin | 1 | 2012 | 31 | 0.030 |
Why?
| Virus Activation | 1 | 2012 | 78 | 0.020 |
Why?
| RNA, Antisense | 1 | 1992 | 17 | 0.020 |
Why?
| Prevalence | 2 | 2010 | 2251 | 0.020 |
Why?
| Herpesvirus 4, Human | 1 | 2012 | 125 | 0.020 |
Why?
| Societies, Medical | 1 | 2015 | 664 | 0.020 |
Why?
| Ligands | 2 | 2005 | 562 | 0.020 |
Why?
| Mass Screening | 1 | 2018 | 1005 | 0.020 |
Why?
| HLA-B15 Antigen | 1 | 2011 | 13 | 0.020 |
Why?
| Sample Size | 1 | 2011 | 112 | 0.020 |
Why?
| Cognition Disorders | 1 | 2015 | 476 | 0.020 |
Why?
| Phagocytosis | 2 | 1983 | 350 | 0.020 |
Why?
| Receptors, Cell Surface | 2 | 1983 | 355 | 0.020 |
Why?
| RNA Splicing | 1 | 1992 | 245 | 0.020 |
Why?
| Thallium Radioisotopes | 1 | 1991 | 7 | 0.020 |
Why?
| Small Molecule Libraries | 1 | 2011 | 79 | 0.020 |
Why?
| Vitamin D-Binding Protein | 1 | 2010 | 13 | 0.020 |
Why?
| HLA-B8 Antigen | 1 | 2010 | 14 | 0.020 |
Why?
| Polymerase Chain Reaction | 2 | 2009 | 993 | 0.020 |
Why?
| Isoantigens | 1 | 1990 | 17 | 0.020 |
Why?
| Amino Acid Substitution | 2 | 2002 | 262 | 0.020 |
Why?
| Receptors, Calcitriol | 1 | 2010 | 53 | 0.020 |
Why?
| Spleen | 3 | 2002 | 487 | 0.020 |
Why?
| Rats, Inbred Strains | 1 | 1990 | 362 | 0.020 |
Why?
| Longitudinal Studies | 1 | 2016 | 2387 | 0.020 |
Why?
| Linkage Disequilibrium | 1 | 2010 | 245 | 0.020 |
Why?
| HLA-DQ beta-Chains | 1 | 2009 | 57 | 0.020 |
Why?
| Chemokines | 1 | 2010 | 216 | 0.020 |
Why?
| Pedigree | 1 | 2010 | 460 | 0.020 |
Why?
| DNA Mutational Analysis | 1 | 2010 | 372 | 0.020 |
Why?
| Immunotherapy, Adoptive | 1 | 1991 | 184 | 0.020 |
Why?
| Microsatellite Repeats | 1 | 2009 | 137 | 0.020 |
Why?
| Homozygote | 1 | 2009 | 187 | 0.020 |
Why?
| Coculture Techniques | 1 | 2009 | 201 | 0.020 |
Why?
| Logistic Models | 1 | 2014 | 1841 | 0.020 |
Why?
| Nausea | 1 | 2009 | 101 | 0.020 |
Why?
| Immunoblotting | 1 | 2009 | 283 | 0.020 |
Why?
| Transplantation, Homologous | 1 | 1990 | 377 | 0.020 |
Why?
| DNA Methylation | 1 | 2013 | 495 | 0.020 |
Why?
| Vomiting | 1 | 2009 | 123 | 0.020 |
Why?
| Coronary Disease | 1 | 1991 | 348 | 0.020 |
Why?
| Immunoglobulin M | 1 | 2009 | 246 | 0.020 |
Why?
| Interferon-alpha | 1 | 2009 | 186 | 0.020 |
Why?
| Genetic Vectors | 1 | 2009 | 289 | 0.020 |
Why?
| Exercise Test | 1 | 1991 | 544 | 0.020 |
Why?
| DNA | 1 | 1994 | 1352 | 0.020 |
Why?
| Mice, Inbred Strains | 1 | 1988 | 396 | 0.020 |
Why?
| DNA-Binding Proteins | 1 | 1994 | 1314 | 0.020 |
Why?
| Cell Line | 2 | 2004 | 2637 | 0.020 |
Why?
| Fever | 1 | 2009 | 280 | 0.020 |
Why?
| Up-Regulation | 1 | 2010 | 808 | 0.020 |
Why?
| Gastrointestinal Diseases | 1 | 2009 | 182 | 0.020 |
Why?
| Retrospective Studies | 3 | 2014 | 12555 | 0.020 |
Why?
| Interleukin-2 Receptor alpha Subunit | 1 | 2007 | 66 | 0.020 |
Why?
| Antisocial Personality Disorder | 1 | 1988 | 156 | 0.020 |
Why?
| Mice, Inbred C57BL | 2 | 2011 | 4694 | 0.020 |
Why?
| Models, Molecular | 1 | 2011 | 1369 | 0.020 |
Why?
| Age Distribution | 1 | 2007 | 342 | 0.020 |
Why?
| NF-kappa B | 1 | 2010 | 641 | 0.020 |
Why?
| Psychotic Disorders | 1 | 1988 | 118 | 0.020 |
Why?
| Chromogranins | 1 | 2006 | 12 | 0.020 |
Why?
| Social Environment | 1 | 1988 | 283 | 0.020 |
Why?
| Phosphorylation | 1 | 2010 | 1569 | 0.020 |
Why?
| Hemodynamics | 1 | 1991 | 1012 | 0.020 |
Why?
| Glucagon | 1 | 2006 | 92 | 0.020 |
Why?
| Mice, Inbred C3H | 2 | 1983 | 239 | 0.020 |
Why?
| Keratins | 1 | 2006 | 176 | 0.020 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2007 | 740 | 0.020 |
Why?
| Thyroglobulin | 1 | 2005 | 17 | 0.020 |
Why?
| Chemokine CXCL11 | 1 | 2005 | 3 | 0.020 |
Why?
| Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 2005 | 14 | 0.020 |
Why?
| Iodide Peroxidase | 1 | 2005 | 27 | 0.020 |
Why?
| Chemokine CXCL9 | 1 | 2005 | 21 | 0.020 |
Why?
| Alprostadil | 1 | 2005 | 32 | 0.020 |
Why?
| Interpersonal Relations | 1 | 1988 | 341 | 0.020 |
Why?
| Chemokine CXCL10 | 1 | 2005 | 34 | 0.020 |
Why?
| Quality of Life | 1 | 2015 | 2353 | 0.010 |
Why?
| Lupus Coagulation Inhibitor | 1 | 1984 | 5 | 0.010 |
Why?
| Fathers | 1 | 2005 | 45 | 0.010 |
Why?
| Antigenic Variation | 1 | 2004 | 9 | 0.010 |
Why?
| Postoperative Complications | 1 | 2015 | 2128 | 0.010 |
Why?
| Dinoprostone | 1 | 2005 | 184 | 0.010 |
Why?
| Mice, Inbred CBA | 1 | 2004 | 49 | 0.010 |
Why?
| Infusion Pumps, Implantable | 1 | 2004 | 20 | 0.010 |
Why?
| Tetanus Toxin | 1 | 2003 | 5 | 0.010 |
Why?
| Chaperonin 60 | 1 | 2003 | 12 | 0.010 |
Why?
| Homeostasis | 1 | 2007 | 573 | 0.010 |
Why?
| Insulin Aspart | 1 | 2004 | 26 | 0.010 |
Why?
| Injections, Subcutaneous | 1 | 2004 | 134 | 0.010 |
Why?
| Fibrosis | 1 | 2006 | 453 | 0.010 |
Why?
| Indicators and Reagents | 1 | 1983 | 99 | 0.010 |
Why?
| Models, Biological | 1 | 1990 | 1621 | 0.010 |
Why?
| Biological Assay | 1 | 1983 | 112 | 0.010 |
Why?
| Fetal Macrosomia | 1 | 2003 | 58 | 0.010 |
Why?
| C-Reactive Protein | 1 | 2005 | 362 | 0.010 |
Why?
| Sex Factors | 1 | 1988 | 1715 | 0.010 |
Why?
| Binding, Competitive | 1 | 1983 | 193 | 0.010 |
Why?
| Interleukin-2 | 1 | 2004 | 413 | 0.010 |
Why?
| Insulin Resistance | 1 | 2010 | 1072 | 0.010 |
Why?
| Antigens, CD1d | 1 | 2002 | 63 | 0.010 |
Why?
| Congenital Abnormalities | 1 | 2003 | 73 | 0.010 |
Why?
| Drug Administration Schedule | 1 | 2004 | 718 | 0.010 |
Why?
| Albuminuria | 1 | 2003 | 164 | 0.010 |
Why?
| Antigens, Surface | 1 | 2002 | 146 | 0.010 |
Why?
| Antigens, Differentiation | 1 | 2002 | 79 | 0.010 |
Why?
| Cell Division | 1 | 2004 | 758 | 0.010 |
Why?
| CTLA-4 Antigen | 1 | 2002 | 76 | 0.010 |
Why?
| Celiac Disease | 1 | 2005 | 264 | 0.010 |
Why?
| Immunohistochemistry | 1 | 2006 | 1629 | 0.010 |
Why?
| Diabetic Ketoacidosis | 1 | 2004 | 159 | 0.010 |
Why?
| Alcoholism | 1 | 1988 | 713 | 0.010 |
Why?
| Major Histocompatibility Complex | 1 | 2002 | 217 | 0.010 |
Why?
| Multivariate Analysis | 1 | 2005 | 1430 | 0.010 |
Why?
| Gestational Age | 1 | 2003 | 760 | 0.010 |
Why?
| Birth Weight | 1 | 2003 | 440 | 0.010 |
Why?
| Alanine | 1 | 2000 | 104 | 0.010 |
Why?
| HLA-DQ alpha-Chains | 1 | 1999 | 14 | 0.010 |
Why?
| Substance-Related Disorders | 1 | 1988 | 947 | 0.010 |
Why?
| Glutamine | 1 | 2000 | 91 | 0.010 |
Why?
| Body Weight | 1 | 2004 | 869 | 0.010 |
Why?
| Aging | 2 | 2007 | 1618 | 0.010 |
Why?
| Mothers | 1 | 2005 | 651 | 0.010 |
Why?
| Incidence | 1 | 2005 | 2313 | 0.010 |
Why?
| Cell Line, Tumor | 1 | 2005 | 2710 | 0.010 |
Why?
| Survival Rate | 1 | 1999 | 1644 | 0.010 |
Why?
| Colorado | 1 | 2005 | 4100 | 0.010 |
Why?
| Trifluoroethanol | 1 | 1994 | 1 | 0.010 |
Why?
| Polydeoxyribonucleotides | 1 | 1994 | 12 | 0.010 |
Why?
| Electrophoresis, Agar Gel | 1 | 1994 | 25 | 0.010 |
Why?
| Sodium Dodecyl Sulfate | 1 | 1994 | 21 | 0.010 |
Why?
| Circular Dichroism | 1 | 1994 | 135 | 0.010 |
Why?
| DNA, Single-Stranded | 1 | 1994 | 111 | 0.010 |
Why?
| Genes, Viral | 1 | 1992 | 89 | 0.010 |
Why?
| Electrophoresis, Polyacrylamide Gel | 1 | 1992 | 318 | 0.010 |
Why?
| Genome, Viral | 1 | 1992 | 118 | 0.010 |
Why?
| Radionuclide Imaging | 1 | 1991 | 115 | 0.010 |
Why?
| Computer Simulation | 1 | 1994 | 873 | 0.010 |
Why?
| Neoplasms | 1 | 1983 | 2097 | 0.010 |
Why?
| Temperature | 1 | 1992 | 565 | 0.010 |
Why?
| Lethal Dose 50 | 1 | 1983 | 12 | 0.000 |
Why?
| Fibrosarcoma | 1 | 1983 | 20 | 0.000 |
Why?
| Leukocytosis | 1 | 1983 | 34 | 0.000 |
Why?
| Hypertension | 1 | 1991 | 1056 | 0.000 |
Why?
| Neoplasm Transplantation | 1 | 1983 | 228 | 0.000 |
Why?
| Leukocyte Count | 1 | 1983 | 293 | 0.000 |
Why?
| Dogs | 1 | 1983 | 334 | 0.000 |
Why?
|
|
Gottlieb's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|